Registry for Asthma Characterization and Recruitment 2
Status: | Recruiting |
---|---|
Conditions: | Asthma |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 1 - 55 |
Updated: | 9/20/2018 |
Start Date: | June 2015 |
End Date: | October 2021 |
Registry for Asthma Characterization and Recruitment 2 (ICAC-25)
There is a need for people to take part in research studies to learn more about diseases and
how to treat them. The Registry for Asthma Characterization and Recruitment 2 (RACR2) will
create a database of participants with asthma and nasal allergies, or risk factors for these
conditions, who are potentially eligible for future Inner City Asthma Consortium (ICAC)
trials. The registry database will include assessments of various asthma and allergy
characteristics to achieve a more efficient, selective recruitment of these participants for
other protocols.
how to treat them. The Registry for Asthma Characterization and Recruitment 2 (RACR2) will
create a database of participants with asthma and nasal allergies, or risk factors for these
conditions, who are potentially eligible for future Inner City Asthma Consortium (ICAC)
trials. The registry database will include assessments of various asthma and allergy
characteristics to achieve a more efficient, selective recruitment of these participants for
other protocols.
The overall goal of the Registry for Asthma Characterization and Recruitment 2 (RACR2) is to
create a database of participants who are potentially eligible for future Inner City Asthma
Consortium (ICAC) clinical research studies. The registry will provide an avenue to assess
various asthma and allergy characteristics, which will result in more efficient recruitment
for current and future ICAC protocols.
Potential participants will be recruited via telephone or in person. Those deemed potentially
eligible for a current protocol or protocol in development may be invited to the clinic for
further data collection and assessments. This registry allows flexibility in selecting the
eligibility criteria and data collection to match planned or upcoming ICAC protocols. At each
stage of data collection, participants may be discontinued, put on hold, or invited to
participate in further screening activities, depending on the likelihood that they will
qualify for a future protocol. Participants may opt to withdraw their information or
discontinue from the registry at any time, in person, by telephone, or in writing.
create a database of participants who are potentially eligible for future Inner City Asthma
Consortium (ICAC) clinical research studies. The registry will provide an avenue to assess
various asthma and allergy characteristics, which will result in more efficient recruitment
for current and future ICAC protocols.
Potential participants will be recruited via telephone or in person. Those deemed potentially
eligible for a current protocol or protocol in development may be invited to the clinic for
further data collection and assessments. This registry allows flexibility in selecting the
eligibility criteria and data collection to match planned or upcoming ICAC protocols. At each
stage of data collection, participants may be discontinued, put on hold, or invited to
participate in further screening activities, depending on the likelihood that they will
qualify for a future protocol. Participants may opt to withdraw their information or
discontinue from the registry at any time, in person, by telephone, or in writing.
Inclusion Criteria:
Eligibility criteria vary depending on recruitment needs for future ICAC protocols.
Participants with asthma and participants without asthma, atopy, and rhinitis may be
recruited at the same time or different times, depending on recruitment needs.
Certain characteristics or groups of characteristics within each criterion may be selected
for periods of time across clinical sites or at each individually participating clinical
site. For example, over a 6-month period, the Consortium could decide to recruit children
aged 6 through 12 years with diagnosed asthma who have asthma symptoms, have a history of
an asthma exacerbation, and reside in prespecified census tracts within the metropolitan
statistical area. During selective recruitment periods, individuals who meet broader
criteria may or may not be enrolled at the discretion of the Consortium.
1. All participants must resides within the metropolitan statistical area that includes
the clinical site.
2. Participants with asthma are defined by having evidence of asthma. Evidence of asthma
is defined by meeting at least one of the following criteria:
- Clinician-diagnosed asthma
- Asthma symptoms, history of an asthma exacerbation, or current use of asthma
medication(s)
- Recurrent wheezing
- Wheezing apart from a cold
At times of selective recruitment, participants with asthma may be required to meet
more selective criteria above and may be required to meet one or more of the criteria
in risk factors for asthma. Evidence of risk factors for asthma is defined by meeting
at least one of the following criteria:
- Parental history of asthma
- Eczema or atopic dermatitis
- Reported allergies to pets, food, indoor allergens, or outdoor allergens
- Allergic sensitization by results of allergy skin testing or results of serum
immunoglobulin E (IgE) testing
- Rhinitis
3. Participants without asthma, atopy, and rhinitis must meet all of the following:
- Negative history of an asthma diagnosis by a clinician
- Negative history of a diagnosis of atopic dermatitis or eczema by a clinician
- Negative history of a rhinitis diagnosis by a clinician
- A forced expiratory volume at 1 second (FEV1) >= 5% predicted
- Negative prick skin-tests to any of a panel of indoor and outdoor allergens
- No current asthma as determined by the appropriate case report form
- No current chronic rhinitis/sinusitis as determined by the appropriate case
report form
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from enrollment:
1. Has any of the following chronic medical conditions: cardiac condition requiring daily
medication, seizure disorder requiring daily medication, obvious severe mental
retardation that prevents the participant from answering questions or following
instructions, cystic fibrosis, immune deficiency, type 1 diabetes, allergic
bronchopulmonary aspergillosis, or any other chronic medical condition at the
discretion of the registry clinician
2. Does not primarily speak English (or Spanish at clinical sites with Spanish-speaking
staff)
3. Has a primary caretaker who does not speak English (or Spanish at clinical sites with
Spanish-speaking staff; not applicable if participant is able to provide consent)
4. Is a foster child (not applicable if participant is able to provide consent)
5. Is unwilling to sign the written informed consent form if of age, or parent/legal
guardian is unwilling to sign the written informed consent if participant is not of
age
6. Is unwilling to sign the assent form, if age appropriate
Participants who are pregnant will not be excluded or discontinued from RACR2 but will not
undergo any procedures that are prohibited during pregnancy.
We found this trial at
10
sites
111 Michigan Ave NW
Washington, District of Columbia
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Stephen Teach, MD, MPH
Phone: 202-476-4698
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Robert A Wood, MD
Phone: 410-614-5467
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials
72 East Concord Street
Boston, Massachusetts 02118
Boston, Massachusetts 02118
(617) 638-5300
Principal Investigator: George O'Connor, MD, MS
Phone: 617-414-3263
Boston University School of Medicine A leader in medical education and research, Boston University School...
Click here to add this to my saved trials
Dallas, Texas 75235
Principal Investigator: Rebecca Gruchalla, MD
Phone: 214-648-2620
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Andrew Liu, MD
Phone: 720-777-8077
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Jacqueline Pongracic, MD
Phone: 312-227-6454
Click here to add this to my saved trials
Cincinnati, Ohio 45229
Principal Investigator: Carolyn Kercsmar, MD
Phone: 513-803-1651
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: Edward Zoratti, MD
Phone: 313-916-6954
Click here to add this to my saved trials
630 W 168th St
New York, New York
New York, New York
212-305-2862
Principal Investigator: Meyer Kattan, MD
Phone: 212-305-6255
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Leonard Bacharier, MD
Phone: 314-286-1290
Click here to add this to my saved trials